Legal Representation
Attorney
Jason S. Howell
USPTO Deadlines
Application History
11 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 20, 2023 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Jul 20, 2023 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Jul 20, 2023 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| Mar 29, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Mar 29, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Jan 5, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 5, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jan 5, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jan 4, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 25, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
| Nov 25, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumors; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy; pharmaceutical and biological preparations for immunotherapy, namely, for use in improving immune evasion, improving cell expansion and potency, and/or reducing rejection by patient immune system
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005